Findings

What do systematic reviews say?

4,667 questions · 21,760 findings · 2,177 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4,173 · 19.2%GRADE not reported 2,300 · 10.6%Very low 5,276 · 24.2%Low 5,764 · 26.5%Moderate 3,298 · 15.2%High 949 · 4.4%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Intervention not reported

Transfer to inpatient care Defined as referral for: presence of danger signs and failed appetite test on first day of treatment (Alvarez Moran 2018)b; appearance of severe signs of illness, persistent oedema, absence of weight gain in non‐oedemato... · children aged > 6 months and < 5 years with wasting

It is very uncertain whether the intervention changes transfer to inpatient care Defined as referral for: presence of… (very low certainty).

1 finding from 1 review

Lay health workers in primary and community health care for maternal and child health: identification and treatment of… 2023 · Cochrane Headline outcomes only
RR 1.42 [1.04, 1.95]
4 studies · 4739 participants
Very low

Summary of findings. Peer reviewer training vs standard journal practice or no training

Stakeholders' assessment of review quality (change score) Assessed using either:A) a 5‐point scale, change scores range from −4 to 4 (3 studies);B) a 5‐point scale, expressed by "slope of quality score change"(1 study); orC) the MQAI, from −144 to... · peer reviewers

1 finding from 1 review

Reviewer training for improving grant and journal peer review 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Plasma rich in growth factors (PRGF) vs Alvogyl

Exposed bone (present versus absent) · Adults (>18 years) with established dry socket following permanent tooth extraction

1 finding from 1 review

Local interventions for the management of alveolar osteitis (dry socket) 2022 · Cochrane All outcomes
Day 7 (also day 3)
PRGF versus Alvogyl (King 2018), exposed bone (% patients): day 3 PRGF 9.1% vs Alvogyl 9.1%; day 7 PRGF 0% vs Alvogyl 22.7% (P<0.05 at day 7)
1 study · 44 participants
GRADE not reported

Summary of findings: anti‐pseudomonal antibiotics vs placebo

FEV1 % predicted · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 1130 participants
Low

Summary of findings: anti‐pseudomonal antibiotics vs placebo

FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 1097 participants
Low

Summary of findings: tobramycin for inhalation powder vs tobramycin

FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 517 participants
Moderate

Summary of findings: aztreonam lysine for inhalation vs tobramycin

FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 268 participants
Moderate

Summary of findings: levofloxacin for inhalation solution vs tobramycin

FEV1 % predicted: relative change from baseline · adults and children aged over 12 with CF and P aeruginosa

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 282 participants
High

Summary of findings: levofloxacin for inhalation solution vs tobramycin

Change in FVC · adults and children aged over 12 with CF and P aeruginosa

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 282 participants
High

Summary of findings: continuous cycles alternating aztreonam lysine for inhalation with tobramycin for inhalation solution vs continuous cycles alternating placebo with tobramycin

FEV1 (% predicted): mean change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 90 participants
Low

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

FEV1 (% predicted): mean change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 374 participants
Low

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 374 participants
Low

Blastocyst‐stage vs cleavage‐stage embryo transfer

Cumulative pregnancy rate (slow freezing) · Patients with subfertility

Blastocyst‐stage may leads to lower cumulative pregnancy rate (slow freezing) compared with cleavage‐stage embryo transfer (low certainty).

1 finding from 1 review

Cleavage‐stage versus blastocyst‐stage embryo transfer in assisted reproductive technology 2022 · Cochrane Headline outcomes only
OR 0.69 [0.48, 0.99]
4 studies · 512 participants
Low

Blastocyst‐stage vs cleavage‐stage embryo transfer

Cumulative pregnancy rate (vitrification) · Patients with subfertility

Blastocyst‐stage probably leads to higher cumulative pregnancy rate (vitrification) compared with cleavage‐stage embryo transfer (moderate certainty).

1 finding from 1 review

Cleavage‐stage versus blastocyst‐stage embryo transfer in assisted reproductive technology 2022 · Cochrane Headline outcomes only
OR 2.44 [1.17, 5.12]
1 study · 120 participants
Moderate

Blastocyst‐stage vs cleavage‐stage embryo transfer

Clinical pregnancy rate · Patients with subfertility

Blastocyst‐stage probably leads to higher clinical pregnancy rate compared with cleavage‐stage embryo transfer (moderate certainty).

1 finding from 1 review

Cleavage‐stage versus blastocyst‐stage embryo transfer in assisted reproductive technology 2022 · Cochrane Headline outcomes only
OR 1.25 [1.12, 1.39]
32 studies · 5821 participants
Moderate

Blastocyst‐stage vs cleavage‐stage embryo transfer

Multiple pregnancy rate · Patients with subfertility

Blastocyst‐stage showed no clear difference in multiple pregnancy rate compared with cleavage‐stage embryo transfer (low certainty).

1 finding from 1 review

Cleavage‐stage versus blastocyst‐stage embryo transfer in assisted reproductive technology 2022 · Cochrane Headline outcomes only
OR 1.12 [0.9, 1.38]
22 studies · 4208 participants
Low

Physical activity vs no physical activity

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Physical activity and exercise training in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 367 participants
Low

Alpha‐blockers vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacotherapy for post traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Comparison 13: SSRIs vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)

Comparison 6: SSRIs probably leads to lower treatment efficacy ‐ treatment response, as measured by the Global… compared with placebo (moderate certainty).

1 finding from 1 review

Pharmacotherapy for post traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
RR 0.66 [0.59, 0.74]
8 studies · 1078 participants
Moderate

Comparison 7: TCAs vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)

Comparison 7: TCAs may leads to lower treatment efficacy ‐ treatment response, as measured by the Global… compared with placebo (low certainty).

1 finding from 1 review

Pharmacotherapy for post traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
RR 0.6 [0.38, 0.96]
1 study · 40 participants
Low